Global Paraganglioma Treatment Market, By Treatment Type (Sympathetic, Parasympathetic Paragangliomas), Site of Origin (Carotid, Cervical, Vagal Paragangliomas and Others), Therapy Type (Radiation Therapy, Chemotherapy, Peptide Receptor Radionuclide Therapy (PRRT) and Others), Drugs (Iobenguane I 131, Cyclophosphamide, Vincristine, Dacarbazine and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights : Global Paraganglioma Treatment Market
The paraganglioma treatment market is expected to gain growth at a potential rate of 9.15% in the forecast period of 2021 to 2028. The rise in research and development activities is the factor responsible for the market growth.
Paraganglioma or glomus tumors is a type of rare type of cancer which occurs in a variety of places in the head and neck or ear certain blood vessels and nerves outside of the adrenal glands. It is ultra-rare neuroendocrine cancer that arise from cells called paraganglia. Paraganglia cells are found near nerve cell bunches called ganglia. Most paraganglioma originate in one of the two adrenal glands located above the kidneys in the back of the upper abdomen. It causes over activation of adrenal hormones that can lead to life-threatening high blood pressure, heart failure, and stroke in these patients. It usually affects both lungs and kidneys. In this syndrome, antibodies are produced against a particular region of collagen in lungs and kidneys.
The rapid rise in the awareness among people regarding the disease is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise the increase in special designation from the regulatory authorities boosts the paraganglioma treatment market growth. Furthermore, the rise in the prevalence of unhealthy lifestyle such as alcoholism and smoking, rise in the healthcare awareness and the continuous advances in the treatment is propelling the market growth market growth rate.
In addition, the rise in the research and development activities, high adoption of healthcare solutions and strong presence of a promising pipeline are likely to create various new opportunities that will impact this paraganglioma treatment market growth in the forecast period of 2021 to 2028.
However, the lack of awareness among people and the limited operating revenue opportunities for research and development of targeted therapies are expected to act as major restraints towards the growth of the paraganglioma treatment market, whereas the lack of healthcare budget in some middle-income countries and the delay in diagnosis of the disease can challenge the growth of the target market in the above mentioned forecast period.
This paraganglioma treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the paraganglioma treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Paraganglioma Treatment Market Scope and Market Size
Paraganglioma treatment market is segmented on the basis of treatment type, site of origin, therapy type, drugs, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment type, the paraganglioma treatment market is segmented into sympathetic and parasympathetic paragangliomas.
- On the basis of site of origin, the paraganglioma treatment market is bifurcated into caroid, cervical, vagal paragangliomas and others.
- On the basis of therapy type, the paraganglioma treatment market is segmented into radiation therapy, chemotherapy, peptide receptor radionuclide therapy and others.
- On the basis of drugs, the paraganglioma treatment market is segregated into iobenguane I 131, cyclophosphamide, vincristine, dacarbazine and others.
- On the basis of route of administration, the paraganglioma treatment market is segmented into oral and injectable.
- Based on end user, the paraganglioma treatment market can be segmented into hospitals, homecare, specialty clinics and others.
- On the basis of distribution channel, the paraganglioma treatment market is segmented into hospital pharmacies, retail pharmacies and others.
Paraganglioma Treatment Market Country Level Analysis
Paraganglioma treatment market is analyzed and market size information is provided by country by treatment type, site of origin, therapy type, drugs, route of administration, end user and distribution channel as referenced above.
The countries covered in the paraganglioma treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the paraganglioma treatment market due to the increase in the prevalence of unhealthy lifestyle. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the rise in geriatric population, increase in the healthcare awareness and the high adoption of healthcare solutions.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Paraganglioma treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Paraganglioma Treatment Market Share Analysis
Paraganglioma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to paraganglioma treatment market.
The major players covered in the paraganglioma treatment market report are Progenics Pharmaceuticals, Inc, AstraZeneca, Advanced Accelerator Applications, Jubilant Life Sciences Ltd, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Cipla Inc, Amneal Pharmaceuticals LLC, Amerigen Pharmaceuticals Limited, Jiangsu Hengrui Medicine Co., Ltd, Fresenius Kabi AG, and ONO PHARMACEUTICAL CO., LTD and others among other domestic and global players. Paraganglioma treatment market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-